May222024Uncategorized Category: UncategorizedBy Charlotte Maddalena22 May 2024 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrinNextNext post:ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire SeniorRelated PostsOrphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024ORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024
Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
